Encore Holdings’ affiliated labs offer tumor panels that take a deeper view of variation in solid tumors in many sites, including lung, colon, melanoma, gastric, and ovarian. Our assay targets 26 genes that are associated with these cancers and provides highly accurate variant analysis at limit of detection below 5% variant allele frequency across 174 amplicons, with 1000x minimum coverage of each region.
How is this assay perfomed? Our labs use small amounts of genomic DNA taken from solid tumors even in FFPE samples.
What is the advantage of this test? Sequencing of genes associated with solid tumor cancers can provide valuable information that may lead to targeted therapies. There are genetic variants in such solid tumors as lung cancer, colon cancer, melanoma, gastric cancer, and ovarian cancer. The assay is performed using small amounts of genomic DNA taken from fresh frozen or paraffin-embedded tumor tissue.
Simply put, our assay helps oncologists, dermatologists, gynecologists, and other physicians target their response to their patients’ cancers in order to give them the most effective care possible.
